Research
Selective mTOR inhibition via FLCN drives TFE3-dependent VLDL-TG secretion and protects from MAFLD/MASH
Nature · By Chelsea L. Thorsheim ·
The Brief
- A Nature Communications study reports a pathway in which selective, non-canonical mTOR signaling via FLCN regulates VLDL assembly and secretion.
- The pathway involves TFE3-dependent VLDL-triglyceride secretion from the liver.
- The authors report that targeting this pathway efficiently suppresses liver steatosis (fatty liver) and protects against MAFLD/MASH.
Why it matters
It identifies a mechanism linking mTOR signaling to hepatic lipid export, a potential target for fatty liver disease (MAFLD) and its progression to MASH.
Who’s affected
- biomedical researchers studying liver metabolism and fatty liver disease
- clinicians and drug developers interested in MASH therapeutics
- #mtor
- #vldl
- #fatty liver
- #mash
- #metabolism
- #flcn
Nature Communications, Published online: 18 November 2026; doi:10.1038/s41467-026-79397-6 The study identified a pathway that coordinates VLDL assembly and secretion regulated by non-canonical mTOR signaling. Targeting the pathway efficiently suppresses liver steatosis.